AMENDMENTS TO THE CLAIMS

1. (currently amended) A ~~vaccine~~ composition for ~~suppressing~~ treating a TH2 response and for inducing a cell mediated immune response comprising a TH1 response in an individual having a TH2/TH1 imbalance associated with a pro-tumor immune response, the ~~vaccine~~ composition comprising: an immunotherapeutic composition for effecting B cell depletion; and tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response.

2. (currently amended) The ~~vaccine~~ composition according to claim 1, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

3. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the immunotherapeutic composition is contained in a solid phase implant for delivery of the immunotherapeutic composition.

4. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

5. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the immunotherapeutic composition comprises an affinity ligand having binding specificity for a determinant selected from the group consisting of CD19, CD20, CD21, CD22 (also known as LL2), CDIM, and Lym-1.

6. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the immunotherapeutic composition comprises cobra venom factor.

7. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

8. (currently amended) The ~~vaccine~~ composition according to claim 1, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

9. (currently amended) A ~~vaccine~~ composition useful for the treatment ~~or prevention~~ of solid nonlymphoid tumor in an individual, the ~~vaccine~~ composition comprising: an immunotherapeutic composition for effecting B cell depletion; and tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective to overcome a TH2/TH1 imbalance, the TH2/TH1 imbalance associated with a pro-tumor immune response, or a combination of the solid nonlymphoid tumor and a pro-tumor immune response.

10. (currently amended) The ~~vaccine~~ composition according to claim 9, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

11. (currently amended) The ~~vaccine~~ composition according to claim 9, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

12. (currently amended) The ~~vaccine~~ composition according to claim 9, wherein the immunotherapeutic composition comprises an affinity ligand having binding specificity for a determinant selected from the group consisting of CD19, CD20, CD21, CD22 (also known as LL2), CDIM, and Lym-1.

13. (currently amended) The ~~vaccine~~ composition according to claim 9, wherein the immunotherapeutic composition comprises cobra venom factor.

14-68. (canceled)

69. (new) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective for suppressing a TH2 response, and for inducing a cell mediated immune response comprising a TH1 response, in an individual having a TH2/TH1 imbalance associated with a pro-tumor immune response.

70. (new) The composition according to claim 69, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

71. (new) The composition according to claim 69, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

72. (new) The composition according to claim 69, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

73. (new) The composition according to claim 70, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

74. (new) The composition according to claim 69, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

75. (new) The composition according to claim 72, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

76. (new) The composition according to claim 71, wherein the immunotherapeutic composition, and the tumor-associated antigen, and the immunomodulator are each separate components that can be administered individually.

77. (new) The composition according to claim 74, wherein the immunotherapeutic composition is contained in a solid phase implant for delivery of the immunotherapeutic composition.

78. (new) The composition according to claim 69, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

79. (new) The composition according to claim 69, wherein the tumor-associated antigen comprises a vaccine antigen.

80. (new) The composition according to claim 69, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

81. (new) The composition according to claim 69, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

82. (new) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an effective amount for the treatment, or inhibition of development, of solid nonlymphoid tumor in an individual having a pro-tumor immune response.

83. (new) The composition according to claim 82, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

84. (new) The composition according to claim 82, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

85. (new) The composition according to claim 82, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

86. (new) The composition according to claim 83, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

87. (new) The composition according to claim 82, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

88. (new) The composition according to claim 85, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

89. (new) The composition according to claim 84, wherein the immunotherapeutic composition, and the tumor-associated antigen, and the immunomodulator are each separate components that can be administered individually.

90. (new) The composition according to claim 82, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

91. (new) The composition according to claim 82, wherein the tumor-associated antigen comprises a vaccine antigen.

92. (new) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22, for effecting B cell depletion in suppressing a TH2 response associated with a pro-tumor immune response or a combination of a pro-tumor immune response and solid nonlymphoid tumor; and

b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response.

93. (new) The composition according to claim 92, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

94. (new) The composition according to claim 93, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

95. (new) The composition according to claim 92, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

96. (new) The composition according to claim 93, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

97. (new) The composition according to claim 92, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

98. (new) The composition according to claim 95, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

99. (new) The composition according to claim 94, wherein the immunotherapeutic composition, and the tumor-associated antigen, and the immunomodulator are each separate components that can be administered individually.

100. (new) The composition according to claim 92, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

101. (new) The composition according to claim 92, wherein the tumor-associated antigen comprises a vaccine antigen.

102. (new) The composition according to claim 92, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

103. (new) The composition according to claim 92, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

104. (new) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion in suppressing a TH2 response; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective to overcome a TH2/TH1 imbalance associated with a pro-tumor immune response, or a combination of solid nonlymphoid tumor and a pro-tumor immune response.

105. (new) The composition according to claim 104, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

106. (new) The composition according to claim 104, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

107. (new) The composition according to claim 104, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

108. (new) The composition according to claim 105, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

109. (new) The composition according to claim 104, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

110. (new) The composition according to claim 107, wherein the immunotherapeutic composition and the tumor-associated antigen are each separate components that can be administered individually.

111. (new) The composition according to claim 106, wherein the immunotherapeutic composition, and the tumor-associated antigen, and the immunomodulator are each separate components that can be administered individually.

112. (new) The composition according to claim 104, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

113. (new) The composition according to claim 104, wherein the tumor-associated antigen comprises a vaccine antigen.

114. (new) The composition according to claim 104, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

115. (new) The composition according to claim 104, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.